Amarin Claims ‘Little Impact’ From Teva’s US Vascepa Generic
Originator Aware Of Potential Fifth Launch From Zydus Cadila
“They have prescriptions just in the hundreds per week, which is in a market of 100,000 or so prescriptions a week,” Amarin has said of Teva’s Vascepa generic, the fourth to reach the US market.
You may also be interested in...
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter
Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.